Perinatal outcome following third-trimester exposure to paroxetine: An alternative interpretation

Archives of Pediatrics and Adolescent Medicine

Volumn 157, Issue 6, 2003, Pages 601-

  Pryse Phillips, William ^a   Yuen, Doris E ^a  

^a GLAXOSMITHKLINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

COGNITIVE DEVELOPMENT; HUMAN; LANGUAGE DEVELOPMENT; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PERINATAL PERIOD; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; TEMPERAMENT; THIRD TRIMESTER PREGNANCY;

FEMALE; HUMANS; INFANT, NEWBORN; PAROXETINE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SEROTONIN UPTAKE INHIBITORS;

EID: 0242586052     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.157.6.601-a     Document Type: Short Survey

References (5)

1. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129-1132.
2. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
3. Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry. 2002;159:1667-1673.
4. Lamberg L. Safety of antidepressant use in pregnant and nursing women. JAMA. 1999;282:222-223.
5. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-262.